(R) -Roscovitine
(R) -Roscovitine (Seliciclib) is an orally bioavailable and selective CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.
Product Specifications
CAS Number
186692-46-6
Product Name Alternative
Seliciclib; CYC202
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/r-roscovitine.html
Purity
99.53
Solubility
DMSO : ≥ 100 mg/mL
Smiles
OC[C@H](NC1=NC(NCC2=CC=CC=C2)=C3C(N(C=N3)C(C)C)=N1)CC
Molecular Formula
C19H26N6O
Molecular Weight
354.45
Precautions
H302, H315, H319, H335
References & Citations
[1]Meijer L, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997 Jan 15;243 (1-2) :527-36.|[2]Bai X, et al. CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via erk1/2/pparγ pathway. Oncotarget. 2016 Apr 27.|[3]Gary C, et al. Selective antitumor activity of roscovitine in head and neck cancer. Oncotarget. 2016 May 23.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CDK1; CDK2; CDK5
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
47195141 1x 10^6 Cells / 1.0 mL
TNFAIP8L2 CRISPR Knock Out 293T Cell Line (Human)
Sign In for Pricing
View Details 
bsm-61288R-PE-Cy5-TR 20 µL
Cyclooxygenase 1 Recombinant Antibody, PE-Cy5 Conjugated
Sign In for Pricing
View Details